The global pharmaceutical landscape is undergoing a pivotal transformation as obesity treatment surges to the forefront of healthcare innovation. One of the central players in this shift, Novo Nordisk $NOVO-B.CO, has recently marked a significant internal development. Lars Rebien Sørensen, the executive who presided over the company’s expansion into diabetes care and R&D-led growth, is making a high-profile return more than a decade after stepping down. His reappearance comes at a critical juncture, as the weight-loss medication Wegovy reshapes the company's market positioning and valuation.